MARKHAM, ON, Feb. 14, 2012 /CNW/ - Cytochroma today announced that Ms.
Ela Borenstein has joined its Board of Directors and that Dr. Peter
Moldt and Mr. Osamu Otani have stepped down. The number of Directors
currently stands at five.
"We are delighted that Ela Borenstein has agreed to join the Cytochroma
Board. She brings a wealth of experience in regulatory affairs, product
development strategy and corporate governance, and will be an
invaluable resource for Cytochroma," stated Dr. Alan Lewis, Chairman.
"We also are grateful for the excellent service rendered by both Peter
Moldt and Osamu Otani as Directors, and we wish them well."
Ms. Borenstein is Partner, Health Venture Fund at the Business
Development Bank of Canada (BDC). She joined BDC in 2007 with over 20
years of management, entrepreneurial and consulting experience in the
biopharmaceutical industry. Prior to joining BDC, she held the
positions of Chief Operating Officer and Vice President of Clinical,
Regulatory Affairs and Product Strategy for various biotech companies,
as well as Senior Vice President of Scientific Affairs for Technilab
Pharma. Ms. Borenstein's diversified background includes senior
management responsibilities in drug and medical device development as
well as key involvement in product acquisition and M&A activities. She
has experience in the building of multi-disciplinary teams involved in
all aspects of research and product development. Ms. Borenstein is
currently serving on the boards of several portfolio companies of BDC's
Health Venture Fund. Ms. Borenstein holds a B.Sc. (Honours) in
Chemistry from the University of Western Ontario, a M.Sc. in
Pharmacology from the University of Toronto and an MBA in
Bio-Industries from Université du Québec à Montréal.
Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and
prevent the clinical consequences of vitamin D insufficiency and
secondary hyperparathyroidism associated with chronic kidney disease
(CKD). The Company specializes in developing new therapies which are
designed to safely and effectively treat patients with stage 3, 4 or 5
CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake
inhibitors in early stage development.
For more information about Cytochroma, please visit www.cytochroma.com.
For further information:
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
Robert Stanislaro (Financial Dynamics)
Tel: +1 (212) 850-5657